MENU
+Compare
PALI
Stock ticker: NASDAQ
AS OF
Jan 22, 10:45 AM (EDT)
Price
$1.47
Change
-$0.04 (-2.65%)
Capitalization
4.48M

PALI Palisade Bio Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds

Industry Biotechnology
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PALI with price predictions
Jan 08, 2025

PALI saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for PALI moved out of overbought territory on January 08, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 37 similar instances where the indicator exited the overbought zone. In of the 37 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

PALI moved below its 50-day moving average on January 08, 2025 date and that indicates a change from an upward trend to a downward trend.

PALI broke above its upper Bollinger Band on January 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on PALI as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in of 199 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.678) is normal, around the industry mean (15.017). P/E Ratio (0.018) is within average values for comparable stocks, (88.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.838). PALI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (11.779) is also within normal values, averaging (265.166).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7750 El Camino Real
Phone
+1 858 704-4900
Employees
9
Web
https://www.palisadebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REXR40.591.59
+4.08%
Rexford Industrial Realty
EBS10.220.34
+3.44%
Emergent Biosolutions
DDD3.140.06
+1.95%
3D Systems Corp
CABO325.26-7.06
-2.12%
Cable One
OST2.26-0.11
-4.64%
Ostin Technology Group Co Ltd

PALI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
+2.03%
RNAC - PALI
81%
Closely correlated
+2.90%
AGEN - PALI
81%
Closely correlated
+10.06%
NCNA - PALI
81%
Closely correlated
+0.88%
SNPX - PALI
81%
Closely correlated
+1.82%
ALLR - PALI
76%
Closely correlated
N/A
More

Groups containing PALI

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
+2.03%
PALI
(7 stocks)
6%
Poorly correlated
-1.08%